Shares of Nano-X Imaging surged +12.2% to $0.80 after the Israeli medical imaging company announced a new partnership to sell its FDA-cleared 3D imaging system across New England. The deal adds a regional partner to a growing list — but the question for shareholders is whether a string of distribution agreements can translate into real revenue before the company's cash runs out.

  • Another Partner, Still No Financial Details Disclosed

Nanox's U.S. subsidiary signed a distribution agreement with Associated X-Ray Imaging Corp., a New England medical equipment provider founded in 1975, which will market, distribute, and support Nanox's FDA-cleared 3D imaging system across the region. No financial terms, volume commitments, or revenue targets were disclosed. This follows at least four similar U.S. distribution deals signed earlier in 2026, with partners including Integrity Medical, Elite Surgical Technologies, Imperial Imaging Technology, and Digital X-Ray Imaging. The cadence of announcements is steady, but none have come with hard numbers investors can model.

  • Revenue Is Growing Slowly While Cash Burns Fast

Nanox reported Q1 2026 revenue of $4.3 million, up from $2.8 million a year earlier, driven mainly by teleradiology services and AI software — not hardware sales.

Yet the company posted a net loss of $14.3 million, and cash fell to $44.2 million from $60 million at year-end 2025. At that burn rate, the runway is roughly three quarters. Management itself stated these resources are insufficient for at least one year, raising "substantial doubt" about the company's ability to continue as a going concern.

  • Agreements Are Piling Up, But Revenue Guidance Was Pulled

Nanox no longer expects to hit its previously announced 2026 revenue target and has stopped providing annual revenue guidance, citing unpredictable deployment and revenue-recognition timelines.

The transition from signed agreements to actual sales is slow, affected by site readiness and regulatory processes. Today's deal, like its predecessors, is a distribution channel — it does not guarantee a single machine gets sold.

  • A Sub-$65 Million Company Facing Class-Action Lawsuits

Nanox's market capitalization sits around $65 million with 78.59 million shares outstanding , down from over $200 million at the start of the year. Multiple securities fraud class-action lawsuits have been filed against the company in recent months.

The stock's 52-week range of $0.71–$4.71 illustrates how dramatically investor confidence has eroded. Today's pop looks more like a short-squeeze on thin volume than a fundamental reassessment.